Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2020-11-08 Regulatory Filings
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Partnership with eCare21 & functional integration completed 3 pages 110.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 November 2020, detailing a partnership agreement between HeraMED Limited and eCare21. It describes the execution of the partnership, integration progress, commercial strategy, and expected benefits. The content focuses on business development and strategic collaboration rather than financial results, regulatory compliance, or management changes. There are no financial statements, audit information, voting results, or executive compensation details. The document is a corporate announcement about a partnership and integration, which fits best under general regulatory announcements or miscellaneous filings that do not fit other categories. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (8948 characters) is sufficient to be a full announcement rather than a brief report publication notice.
2020-11-08 English
Quarterly Activities & Cashflow Report 9 pages 306.9KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 October 2020 providing a quarterly update for the three months ending 30 September 2020 (Q3 FY20). It includes detailed operational highlights, clinical study results, partnership updates, financial overview including cash flow and expenditure against prospectus budget, and an Appendix 4C quarterly cash flow report as required by ASX Listing Rule 4.7B. The document contains substantive financial data and analysis for the quarter, including cash flows from operating and investing activities, expenditure breakdowns, and commentary on variances. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the correct classification is IR with high confidence. Q3 2020
2020-10-28 English
Updated Investor Presentation 25 pages 4.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about HeraMED's digital maternity care technology, including clinical trial results, product descriptions, commercial strategy, partnerships, and future growth plans. It contains no financial statements, regulatory filings, or formal report structures typical of annual or interim reports. The content is focused on explaining the company's technology, market opportunity, and commercialization plans, which aligns with an investor presentation. The document length is substantial and contains detailed slides and data, consistent with an Investor Presentation (IP). There is no indication that this is an announcement of a report or a regulatory filing, nor is it a transcript or legal proceeding. Therefore, the best classification is Investor Presentation (IP).
2020-10-20 English
Amended Updated Investor Presentation 26 pages 4.2MB
Investor Presentation Classification · 95% confidence The document is titled 'Amended Investor Presentation' and is dated 21 October 2020. It explicitly refers to an updated investor presentation and includes detailed slides about the company's business model, clinical trials, product features, commercial strategy, and growth horizons. The content is typical of an investor presentation aimed at providing financial, strategic, and operational insights to investors. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The document is not a brief announcement or a regulatory filing but a detailed presentation. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-10-20 English
Clinical & Functional Validation of HeraBEAT Achieved at JHC 3 pages 141.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 October 2020, detailing the results of a clinical study validating the HeraBEAT device's accuracy and usability. It focuses on clinical validation, user satisfaction, and commercial strategy rather than financial results or regulatory filings. There is no indication of financial statements, management discussion, or regulatory certifications. The content is a company announcement about clinical study outcomes and commercial implications, not a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or company update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS). The document length (8003 characters) and detailed content confirm it is not a brief report publication announcement or a certification letter.
2020-10-07 English
HMD Clinical Study Results Conference Call 1 page 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 October 2020 about a conference call to discuss clinical study results. It includes details for the call, the speakers, and how to register. There is no financial data, no detailed report, and no indication that this is a transcript or a full report. The document is short (2345 characters) and serves as an announcement for an upcoming conference call. Therefore, it fits the category of a Call Transcript (CT) announcement or a conference call announcement. However, since it is not a transcript but an announcement of a conference call, it is best classified as a Regulatory Filing (RNS) because it does not fit other categories and is an announcement-type document.
2020-10-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.